The effect of ticagrelor and clopidogrel on angiographic parameters according to diabetic status in patients with ST elevation myocardial infarction

Aydınyılmaz, Faruk; Sunman, Hamza; Algül, Engin; İBİŞ, Ayşenur ÖZKAYA; Özbeyaz, Nail Burak; Guliyev, İlkin; Erzurum, Muhammed; Çi̇men, Tolga; Tulmaç, Murat

doi:10.15829/1560-4071-2022-5021

Cited by 2 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In-hospital GRACE score > 140 is considered as increased risk of mortality. In addition, recent studies have proposed a variety of parameters to predict the outcomes of ACS patients [ 16 – 19 ]. In this study, we found that serum Cys-C level was correlated positively with GRACE score at admission and after discharge, indicating that serum Cys-C level may be used for early risk stratification.…”

Section: Discussionmentioning

confidence: 99%

Serum cystatin C predicts the risk of non-ST-elevation acute coronary syndrome

Dong,

Xiao,

Tang

2023

J Cardiothorac Surg

View full text Add to dashboard Cite

Objective Inflammation markers have been proposed as the predictors of adverse cardiac events in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). This study aimed to investigate prognostic value of serum cystatin C (Cys-C) for NSTE-ACS patients. Methods Cys-C, neutrophil to lymphocyte ratio (NLR) and high-sensitivity C-reactive protein (hsCRP) were examined in 212 NSTE-ACS patients and 60 controls. Global registry of acute coronary events (GRACE) score and major adverse cardiac events (MACE) in NSTE-ACS patients were recorded. Results Cys-C level in the serum was significantly higher in NSTE-ACS patients than in control, and was positively correlated with hsCRP level and NLR as well as GRACE score at admission and 6 months after discharge in NSTE-ACS patients. Serum Cys-C level was identified as a new predictor of MACE. Conclusion Serum Cys-C level may be an inflammation biomarker in patients with NSTE-ACS, and could be used as an independent predictor of MACE.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum cystatin C predicts the risk of non-ST-elevation acute coronary syndrome

Dong,

Xiao,

Tang

2023

J Cardiothorac Surg

View full text Add to dashboard Cite

show abstract

“…Aydınyılmaz et al. [ 37 ] found that ticagrelor was superior in terms of angiographic parameters regardless of diabetes, and clopidogrel efficiency was found to be lower than ticagrelor, especially in patients with no-reflow and higher HbA1c levels. Our study suggests that HbA1c can effectively predict the risk of MACCE in anemia patients with PCI.…”

Section: Risk Stratificationmentioning

confidence: 99%

Risk stratification algorithm for clinical outcomes in anemic patients undergoing percutaneous coronary intervention

Ke,

Gong,

Shen

et al. 2023

Annals of Medicine

View full text Add to dashboard Cite

Background To explore the crosstalk between baseline or visit hemoglobin and major adverse cardiovascular and cerebral events (MACCE) in percutaneous coronary intervention (PCI) patients and to construct risk stratification models to predict MACCE amongst these patients. Materials and methods We conducted a retrospective cohort in patients undergoing PCI procedures at Beijing Friendship Hospital between January 2013 and December 2020. Multivariate Cox proportional hazards models were employed for data analyses. The composite MACCE was the primary endpoint and we used machine learning algorithms to evaluate risk factors associated with MACCE. Model performance was measured using Brier scores and receiver-operating characteristic curves. The association between risk factors and MACCE probability was examined using partial dependency plots. Results 8,298 PCI-treated patients were enrolled in the study. 1,919 of these patients had anemia. During a four-year median follow-up period, 1,636 patients (19.71%) had MACCE. The visit hemoglobin and hemoglobin change was associated with higher risk of MACCE respectively (visit hemoglobin: hazard ratio [HR]: 0.98; 95% confidence interval [CI]: 0.98–0.99; p < 0.001; hemoglobin change: HR: 0.99; 95%CI: 0.98–0.99; p < 0.001). Gradient Boosting (GB) was the BPM, with a mean C-statistic value of 0.78 (95% CI: 0.76–0.80) for predicting MACCE (Brier score: 0.26). The best indicator for MACCE was a low estimated glomerular filtration rate [eGFR] (71 mL/min/1.73m 2 ) at admission, followed by a high serum HbA1c (6.6%) level. A simple risk tree successfully classified patients (17–40.5%) with increased risks of MACCE. The high- vs. low-risk HR for MACCE was 2.04 (95% CI: 1.48–2.82). Conclusions Visit hemoglobin and long-term hemoglobin changes were more predictive of MACCE risk than baseline hemoglobin levels. Our findings indicated that increasing hemoglobin levels might improve the long-term prognosis of anemia patients. We established a new risk stratification model for MACCE, which may more efficiently prioritize targeted screening for at-risk anemic patients undergoing PCI.

show abstract

The effect of ticagrelor and clopidogrel on angiographic parameters according to diabetic status in patients with ST elevation myocardial infarction

Cited by 2 publications

References 34 publications

Serum cystatin C predicts the risk of non-ST-elevation acute coronary syndrome

Serum cystatin C predicts the risk of non-ST-elevation acute coronary syndrome

Risk stratification algorithm for clinical outcomes in anemic patients undergoing percutaneous coronary intervention

Contact Info

Product

Resources

About